GU Cancers 2026 | Managing peripheral neuropathy in EV-treated urothelial carcinoma
Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses findings from a Delphi study developing consensus guidance on early identification and management of peripheral neuropathy in patients with urothelial carcinoma receiving enfortumab vedotin (EV). The analysis reviewed multiple studies highlighting challenges in peripheral neuropathy assessment, including patient underreporting and clinician underestimation of symptom severity. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’re very excited at the GU ASCO 2026 to present our data on the Delphi panel. So it was a group of providers including medical oncologists, neurologists, physiatrists, physical therapy, and even a patient advocate. And we all sat together and we went over the literature and what is the best way to try to identify neuropathy in patients that are receiving infortumab vedotin and how can we actually be able to do early recognition in order to manage this toxicity and try to keep patients on treatment as long as possible to drive the best benefit...
We’re very excited at the GU ASCO 2026 to present our data on the Delphi panel. So it was a group of providers including medical oncologists, neurologists, physiatrists, physical therapy, and even a patient advocate. And we all sat together and we went over the literature and what is the best way to try to identify neuropathy in patients that are receiving infortumab vedotin and how can we actually be able to do early recognition in order to manage this toxicity and try to keep patients on treatment as long as possible to drive the best benefit.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
